RISE Life Science Provides Operational Update
RISE Life Science Corp. (CSE:RLSC) (the “Company” and/or “RISE”), today provided an operational update on its plans and projected timelines for the 2018 calendar year. RISE is pleased to announce that it expects to launch its own commercial products for sale in the California market on or about its previously announced launch date of 6/20/2018.
“With the recent introduction of the RISE Report on SEX and Cannabis our longitudinal cannabis and sex study, followed by the launch of our digital publication, RISE Mag (http://riselifescience.com/rise-mag/), which just completed featured coverage of the recent Lift event in Toronto, we have already executed against a number of key milestones,” said Anton Mattadeen, CEO of RISE. “In this activity update we are pleased to share that our targeted product rollout in the California market is on schedule. It will begin with our suite of CBD sexual health products, followed by CBD topical products in early calendar Q3 2018, coinciding with the launch of our full CBD suite of sexual health products in other legal jurisdictions. The Company is also planning a CBD-based beverage line of products in multiple markets within the next 12 months.”
RISE products are expected to be available in California retail locations by the end of July and will be offered through dispensaries initially, followed by health food retailers and natural wellness boutiques. Chris Dollard, COO of RISE stated that “Addressing sexual health and wellness is a deeply personal decision that requires both excellent communication protocols and discretion. We want the retail experience to be comfortable, enlightening, and above all – fun. Communicating the right information in the right way is a key process for us and the main reason why we are so selective about our retail partnerships.”
All RISE products are designed to appeal to the conventional mass adult market. The Company is therefore planning to utilize other mainstream health and wellness retail distribution points beyond dispensaries to widen availability. Mr. Mattadeen further stated that “Our CBD baseline supported by our cannabis and sex longitudinal research study enables us to provide products and information that fits perfectly within any health and wellness retail environment, and is the only suite of CBD products supported by open, ongoing behavioral research efforts. As the importance of CBD continues to gain traction as an important product set for trusted local and national health retailers, RISE sexual health and wellness products will be well positioned to become a big part of that story.”
Longer term, the Company’s goals include establishing the capacity in 2019 to market its full spectrum of CBD products in the United States, Canada and Europe. Beyond 2019, the Company’s expansion goals include seeking marketing and manufacturing partnerships in the Asia-Pacific region, while continuing to deepen and expand its range of products.
About RISE Life Science Corp.
RISE Life Science Corp. develops cutting-edge cannabis consumer products for both medical and adult-use markets around the world in jurisdictions that have legal regulatory frameworks in place. All products are based on patent-pending formulations and processes to produce specifically targeted effects. A key area of focus for RISE is research-based formulations to address adult sexual health and wellness for both women and men.
Cautionary Statement Regarding Forward-Looking Information
The Canadian Securities Exchange has not reviewed this news release and does not accept responsibility for the adequacy or accuracy of this news release.
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in RISE’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should, target, goals, projections, anticipated” and similar expressions, are forward- looking statements. Forward-looking statements may include, without limitation, statements including the Company’s expectations with respect to pursuing new opportunities and its future growth and other statements of fact.
Although RISE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: general economic conditions; pending and proposed legislative or regulatory developments including the impact of changes in laws, regulations and the enforcement thereof; reliance on funding models; operational and infrastructure risks including possible equipment failure and performance of information technology systems; intensifying competition resulting from established competitors and new entrants in the businesses in which the Company operates; insurance coverage of sufficient scope to satisfy any liability claims; fluctuations in total customers; technological change and obsolescence; loss of services of key senior management personnel; privacy laws; leverage and restrictive covenants; fluctuations in cash timing and amount of capital expenditures; tax-related risks; unpredictability and volatility of the price of the Company’s securities; dilution; and future sales of the Company’s securities. Further risks include operational risks of operating in the U.S.; U.S. federal regulation risks; variation in U.S. state regulations; change of U.S. cannabis laws; security risks; risks related to permits and authorizations; risks on liability, enforcement complaints etc.; banking risks; marketing, sales, manufacturing and distribution risk regarding our product growth plans; changes in laws; limited operating history; reliance on management; requirements for additional financing; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change. There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. RISE disclaims any intention or obligation to update or revise such information, except as required by applicable law, and RISE does not assume any liability for disclosure relating to any other company mentioned herein.
For more information, please contact:
Communication Director, RISE Life Science
President & CEO